Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Bluejay Diagnostics (BJDX) AI Stock Analysis

179 Followers
BJDX

Bluejay Diagnostics

(NASDAQ:BJDX)

Select Model
Rating:44Neutral
Price Target:$1.50▼(-46.43% Downside)
Action:reiterated
Date:04/08/26

The score is held down primarily by very weak financial performance (minimal revenue, ongoing losses, and persistent cash burn). Technicals add a mildly negative signal given the stock remains below key longer-term moving averages with negative MACD. Corporate events are a modest positive due to clinical and manufacturing progress, but they do not offset the current loss-making profile and funding/dilution overhang; valuation also offers limited support given negative earnings and no dividend.

Positive Factors
Pivotal SYMON‑II enrollment nearing completionNear-complete pivotal enrollment materially shortens the regulatory pathway timeline and reduces clinical execution risk. Successful completion enables analysis to support a 510(k), strengthening the firm’s ability to commercialize a rapid IL-6 sepsis diagnostic and convert R&D investment into a marketable product.
Negative Factors
Persistent negative cash flowSustained multi‑million negative operating and free cash flow creates ongoing funding needs and heightens execution risk until revenue materializes. Even with some improvement, persistent burn compels dilution or external financing, limiting ability to invest opportunistically in commercialization or scale.

Bluejay Diagnostics (BJDX) vs. SPDR S&P 500 ETF (SPY)

-100%-75%-50%-25%0%25%BJDX-88.18%SPY+14.28%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$3.13M
Dividend Yield
―
Average Volume (3M)
329.64K
Price to Earnings (P/E)
-0.1
Beta (1Y)
-0.47
Revenue Growth
―
EPS Growth
93.91%
Country
US
Employees
6
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Bluejay Diagnostics Business Overview & Revenue Model

Company Description

Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestra...

How the Company Makes Money

null

Bluejay Diagnostics Financial Statement Overview

Summary

Fundamentals are weak: revenue is effectively absent and losses remain large (multi-million-dollar net losses), with persistent operating and free-cash-flow burn. Offsetting positives are very low leverage and positive equity in recent years, plus some narrowing of losses/cash outflows, but overall execution and funding risk remain high until revenue scales.

Income Statement

12Very Negative

Balance Sheet

48Neutral

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue0000249.04K0
Gross Profit-98.37K00048.91K0
EBITDA-7.09M-6.68M-6.70M-9.17M-8.99M-2.98M
Net Income-7.27M-6.85M-7.72M-9.95M-9.30M-3.73M
Balance Sheet
Total Assets11.53M7.12M6.66M4.87M13.52M21.02M
Cash, Cash Equivalents and Short-Term Investments9.60M5.16M4.30M2.21M10.11M19.05M
Total Debt80.67K120.21K222.25K352.98K492.62K0
Total Liabilities2.12M1.14M927.92K1.97M1.98M637.16K
Stockholders Equity9.41M5.98M5.73M2.89M11.54M20.38M
Cash Flow
Free Cash Flow-6.24M-6.23M-8.13M-9.02M-8.94M-4.39M
Operating Cash Flow-5.90M-6.05M-7.82M-8.31M-7.74M-4.37M
Investing Cash Flow-331.82K-173.74K-306.78K-704.17K-1.20M-23.95K
Financing Cash Flow11.39M7.09M10.22M1.11M8,07522.53M

Bluejay Diagnostics Technical Analysis

Technical Analysis SentimentNeutral
Last Price2.80

Price Trends

50DMA3.10Negative
100DMA4.09Negative
200DMA7.00Negative

Market Momentum

MACD-0.17Negative
RSI53.39Neutral
STOCH82.37Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BJDX, the sentiment is Neutral. The current price of 2.80 is above the 20-day moving average (MA) of 2.48, below the 50-day MA of 3.10, and below the 200-day MA of 7.00, indicating a neutral trend. The MACD of -0.17 indicates Negative momentum. The RSI at 53.39 is Neutral, neither overbought nor oversold. The STOCH value of 82.37 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BJDX.

Bluejay Diagnostics Risk Analysis

Bluejay Diagnostics disclosed 58 risk factors in its most recent earnings report. Bluejay Diagnostics reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.The Class C Warrants may have an adverse effect on the market price of our common stock and make it more difficult to affect a business combination.Q3, 2024
2.Sales of substantial amounts of our securities in the public market could depress the market price of our common stock.Q3, 2024
3.We have incurred significant losses since our inception, do not currently generate any operating income, and will continue to incur losses as we work to obtain product approval, and thus we may never achieve or maintain profitability.Q3, 2024

Bluejay Diagnostics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

BJDX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AEMDAEMD50Neutral$8.90M-0.47-123.09%――87.54%
BJDXBJDX44Neutral$3.14M-0.07-125.01%――93.91%
DHAIDHAI40Underperform$8370.0024.90%―――

* Healthcare Sector Average

Performance Comparison

-75%-50%-25%0%BJDXAEMDBBLGDHAIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
BJDX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
BJDXBluejay Diagnostics, Inc.2.80-22.00-88.71%
AEMDAethlon5.53-18.17-76.67%
BBLGBone Biologics Corp0.35-1.35-79.41%
DHAIDIH Holdings US, Inc Class A0.02-0.53-96.36%

Bluejay Diagnostics Corporate Events

Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance

Bluejay Diagnostics Completes Enrollment in SYMON-II Sepsis Study

Positive
Jul 22, 2026

On July 21, 2026, Bluejay Diagnostics announced it had completed patient enrollment in its SYMON-II multicenter clinical validation study ahead of schedule, reaching the target of 750 intensive-care sepsis patients. Conducted across leading U.S. inst...

Business Operations and StrategyExecutive/Board ChangesShareholder MeetingsStock Split

Bluejay Diagnostics Shareholders Approve Stock Plan and Flexibility

Positive
Jun 9, 2026

At its June 9, 2026 annual meeting, Bluejay Diagnostics shareholders re-elected all incumbent directors and ratified Wolf & Company, P.C. as the independent auditor for the 2026 fiscal year, with quorum achieved from 414,092 of 1,034,715 eligible sha...

Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance

Bluejay Diagnostics Completes Private Placement to Extend Runway

Positive
Jun 8, 2026

On June 2, 2026, Bluejay Diagnostics entered into securities purchase and registration rights agreements with institutional and accredited investors for a private placement of pre-funded warrants and Series G and H warrants tied to 3,655,917 shares o...

Business Operations and Strategy

Bluejay Diagnostics Forms U.S. Manufacturing Partnership for Symphony

Positive
Jun 2, 2026

On May 27, 2026, Bluejay Diagnostics entered an agreement with Argonaut Manufacturing Services for a suite of manufacturing services to support its Symphony platform and IL-6 testing products. The deal covers planning, engineering, supply chain manag...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Apr 08, 2026